The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care

Precision medicine holds real promise for the treatment of cancer. Adapting therapeutic strategies so patients receive individualized treatment protocols, will transform how diseases like cancer are managed. Already, molecular profiling technologies have provided unprecedented capacity to characterize tumors, yet the ability to translate this to actionable outcome in the clinic is limited. To enable real time translation of personalized therapeutic approaches to patient care in a co-clinical manner will require the adoption and integration of approaches that facilitate modeling of patient disease. The Mouse Hospital represents an approach that is ideally suited to pre- and co-clinical evaluation of novel therapeutic strategies for clinical care. Patient derived xenograft (PDX) technologies and in situ tumor modeling approaches using genetically engineered mouse models (GEMMs) already have a proven capacity to mimic human tumor responses, and their application can deliver invaluable insights into appropriate clinical approaches for individual patients by mirroring human clinical trials using a Co-Clinical Trial project and Mouse Hospital infrastructure. Additionally, the integration of the Mouse Hospital with other emerging technologies for the application of precision medicines, including organoid technologies, provides a platform that enables medical centers to truly reap the benefits that precision medicine has to offer.

• Publication year

  2018

• Venue

  Frontiers in Oncology

• Publication date

  2018-08-28

• Fields of study

  Medicine, Computer Science, Engineering

• Identifiers
  DOI 10.3389/fonc.2018.00340PMID 30211119PMCID 6122291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms

  2018cited by this paper
• A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

  2018cited by this paper
• An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.

  2018cited by this paper
• Evolving field

  2018cited by this paper
• A surgical orthotopic organoid transplantation approach in mice to visualize and study colorectal cancer progression

  2018cited by this paper
• Colonoscopy-based colorectal cancer modeling in mice with CRISPR–Cas9 genome editing and organoid transplantation

  2018cited by this paper
• Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field

  2018cited by this paper
• Interrogating open issues in cancer precision medicine with patient-derived xenografts

  2017cited by this paper
• Patient-derived xenografts undergo murine-specific tumor evolution

  2017cited by this paper
• Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

  2017cited by this paper
• Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.

  2017cited by this paper
• Higher-Order Kidney Organogenesis from Pluripotent Stem Cells.

  2017cited by this paper
• Can cancer researchers accurately judge whether preclinical reports will reproduce?

  2017cited by this paper
• Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

  2017cited by this paper
• An immunogenic personal neoantigen vaccine for patients with melanoma

  2017cited by this paper
• BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance

  2017cited by this paper
• Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

  2016cited by this paper
• Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

  2016cited by this paper
• Translating cancer genomes and transcriptomes for precision oncology

  2016cited by this paper
• Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland

  2016cited by this paper
• Abstract PR01: Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids

  2016cited by this paper
• CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.

  2016cited by this paper
• A Landscape of Pharmacogenomic Interactions in Cancer

  2016cited by this paper
• Mouse models in oncoimmunology

  2016cited by this paper
• A co-clinical platform to accelerate cancer treatment optimization.

  2015cited by this paper
• Prospective derivation of a living organoid biobank of colorectal cancer patients.

  2015cited by this paper
• Preclinical mouse cancer models: a maze of opportunities and challenges.

  2015cited by this paper
• Mouse genome engineering via CRISPR-Cas9 for study of immune function.

  2015cited by this paper
• Correlating chemical sensitivity and basal gene expression reveals mechanism of action

  2015cited by this paper
• High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

  2015cited by this paper
• Mouse hospital and co-clinical trial project—from bench to bedside

  2015cited by this paper
• Organoid cultures derived from patients with advanced prostate cancer.

  2014cited by this paper
• Mouse tumour models to guide drug development and identify resistance mechanisms

  2014cited by this paper
• Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules.

  2014cited by this paper
• An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

  2013cited by this paper
• Infrastructure needs for translational integration of mouse and human trials.

  2013cited by this paper
• A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

  2013cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• The APL paradigm and the "co-clinical trial" project.

  2011cited by this paper
• Kinetics of haematopoietic recovery after dose‐intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha

  2003cited by this paper

• Ex-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis

  2025cites this paper
• Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice

  2023cites this paper
• Phenotypic drug discovery: recent successes, lessons learned and new directions

  2022cites this paper
• Patient-Derived In Vitro and In Vivo Models of Cancer.

  2022cites this paper
• A new sophistication for breast cancer PDXs

  2022cites this paper
• In Vivo Models for Prostate Cancer Research

  2022cites this paper
• Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model

  2022cites this paper
• Mouse avatars of human cancers: the temporality of translation in precision oncology

  2021cites this paper
• Toward improved models of human cancer

  2021cites this paper
• In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles.

  2021cites this paper
• Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma

  2021cites this paper
• Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

  2021cites this paper
• Preclinical models in oncological pharmacology: limits and advantages

  2021cites this paper
• Future Perspective of Diabetic Animal Models

  2020cites this paper
• Patient-derived tumour models for personalized therapeutics in urological cancers

  2020cites this paper
• Current methods in translational cancer research

  2020cites this paper
• In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

  2020cites this paper
• Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy

  2020cites this paper
• Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models

  2020cites this paper
• The role of mouse tumour models in the discovery and development of anticancer drugs

  2019cites this paper
• Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors

  2019cites this paper